ArticlePharmaceuticals (Basel, Switzerland)2023

Human Mesenchymal Stem Cell (hMSC) Donor Potency Selection for the "First in Cystic Fibrosis" Phase I Clinical Trial (CEASE-CF).

Tracey L Bonfield et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.